| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10006-010-0224-Y |
| P698 | PubMed publication ID | 20401503 |
| P50 | author | Christian Walter | Q46500866 |
| P2093 | author name string | Wilfried Wagner | |
| Elke Jäger | |||
| Torsten Hansen | |||
| Felix P Koch | |||
| P2860 | cites work | Actinomycosis of the jaws--histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis | Q33303395 |
| Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer | Q33369361 | ||
| Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. | Q33379941 | ||
| Role of tyrosine kinase inhibitors in cancer therapy | Q34432091 | ||
| Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies | Q34564857 | ||
| Flt3 receptor tyrosine kinase as a drug target in leukemia | Q35794059 | ||
| Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis. | Q36581476 | ||
| Sunitinib: from rational design to clinical efficacy | Q36747062 | ||
| Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancer | Q36915973 | ||
| The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway | Q37239237 | ||
| Osteoradionecrosis of the jaws--a current overview--part 1: Physiopathology and risk and predisposing factors | Q37684870 | ||
| Pharmacokinetic and pharmacological aspects of interferon therapy in man | Q40101772 | ||
| Microvascular pericytes express platelet-derived growth factor-beta receptors in human healing wounds and colorectal adenocarcinoma. | Q42050115 | ||
| Pharmacokinetics of vinorelbine in man. | Q43783025 | ||
| Osteonecrosis of the jaws by long term therapy with bisphosphonates | Q44117756 | ||
| In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. | Q44285254 | ||
| Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone | Q46124362 | ||
| Osteonecrosis of the jaw under bisphosphonate and antiangiogenic therapies: cumulative toxicity profile? | Q46136060 | ||
| Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. | Q46320594 | ||
| Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. | Q46500802 | ||
| Sunitinib: a cause of bullous palmoplantar erythrodysesthesia, periungual erythema, and mucositis | Q46798568 | ||
| Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma | Q46837791 | ||
| Sunitinib and Hypothyroidism | Q59571760 | ||
| Osteonecrosis of the jaws: a complication of cancer chemotherapy | Q71859107 | ||
| New foundations in understanding osteonecrosis of the jaws | Q75414575 | ||
| Osteonecrosis of the jaw, a recently recognized sequela of bisphosphonate therapy: case report | Q81652321 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 63-66 | |
| P577 | publication date | 2011-03-01 | |
| P1433 | published in | Oral and maxillofacial surgery | Q27721906 |
| P1476 | title | Osteonecrosis of the jaw related to sunitinib. | |
| P478 | volume | 15 |
| Q47252665 | A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer |
| Q46713930 | Analysis of reasons for osteonecrosis of the jaws |
| Q55265048 | Angiogenesis in the Development of Medication-Related Osteonecrosis of the Jaws: An Overview. |
| Q38831851 | Bisphosphonate-related osteonecrosis of the jaw: from the sine qua non condition of bone exposure to a non-exposed BRONJ entity. |
| Q34870857 | Bisphosphonates' antiangiogenic potency in the development of bisphosphonate-associated osteonecrosis of the jaws: influence on microvessel sprouting in an in vivo 3D Matrigel assay. |
| Q55094789 | Delayed Diagnosis of Osteonecrosis of the Jaw (ONJ) Associated with Bevacizumab Therapy in Colorectal Cancer Patients: Report of Two Cases. |
| Q46146438 | Does CBCT alter the diagnostic thinking efficacy, management and prognosis of patients with suspected Stage 0 medication-related osteonecrosis of the jaws? |
| Q30888611 | Existing data sources for clinical epidemiology: Scandinavian Cohort for osteonecrosis of the jaw - work in progress and challenges. |
| Q57904464 | Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: Report of 2 cases with clinical implications |
| Q55068672 | Isoprenoid geranylgeraniol: the influence on cell characteristics of endothelial progenitor cells after bisphosphonate therapy in vitro. |
| Q55025928 | Meth Mouth—A Growing Epidemic in Dentistry? |
| Q38584982 | New cancer therapies and jaw necrosis |
| Q35705188 | Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review |
| Q26827072 | Osteochemonecrosis: an overview |
| Q38807483 | Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology |
| Q55332559 | Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-Naïve Patient: A Comprehensive Review of the Literature. |
| Q40560466 | Osteonecrosis of the Jaw in the Absence of Antiresorptive or Antiangiogenic Exposure: A Series of 6 Cases |
| Q37525339 | Osteonecrosis of the jaw associated with ziv-aflibercept |
| Q64101769 | Osteonecrosis of the jaw in the era of targeted therapy and immunotherapy in oncology |
| Q57800097 | Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review |
| Q64277201 | Osteonecrosis of the jaws produced by sunitinib: a systematic review |
| Q37006852 | Pathophysiology of Osteonecrosis of the Jaws |
| Q38705715 | Risk factors for medication-related osteonecrosis of the jaws: A systematic review. |
| Q92148335 | Risk profile for antiangiogenic agent-related osteonecrosis of the jaws |
| Q37009387 | Serum Markers of Bone Turnover and Angiogenesis in Patients With Bisphosphonate-Related Osteonecrosis of the Jaw After Discontinuation of Long-Term Intravenous Bisphosphonate Therapy |
| Q84323419 | Sunitinib related osteonecrosis of jaw: a case report |
| Q89418216 | The influence of geranylgeraniol on microvessel sprouting after bisphosphonate substitution in an in vitro 3D-angiogenesis assay |
| Q93346859 | [Progress on medication-related osteonecrosis of the jaw] |
Search more.